Home

MedImmune, which incorporates the former Cambridge Antibody Technology (CAT) as of 29 October 2007, is committed to advancing science to develop better medicines that help people live healthier, longer and more satisfying lives. MedImmune is a biotechnology company wholly owned by AstraZeneca plc.